Slides
Page 1
PI Industries Ltd. Investor Presentation Q1 FY27 Result PI Industries Limited Sanjay Agarwal sanjay.agarwal@piind.com Tel : +91 22 6266 5600 Fax : +91 22 6266 5765 CDR India Siddharth Rangnekar siddharth@cdr-india.com Nishid Solanki nishid@cdr-india.com Tel : +91 22 6645 1221/1209 Fax : +91226645 1213 Pi A Certain statements made in this presentation may not be based on historical information or facts and may be " forward looking statements , cluding those relating to general business plans and strategy of PI Industries Limited ( " PIIL " ) ( including its subsidiaries ) , its future outlook and growth prospects , and future developments in its businesses and its competitive and regulatory environment . Such forward looking statements are subject to certain risks and uncertainties like regulatory changes , local political or econom developments , and many other factors that could cause the actual results to differ materially from those contemplated by the relevant forward - looking statements , which are based upon what management of the Company believes are reasonable assumptions . This could also differ due to a number of other factors , including future changes or developments in PIIL's business , its competitive environment , its ability to implement its strategies and initiatives and respond to technological changes . This presentation does not constitute a prospectus , offering circular or offering memorandum or an offer , or a solicitation of any offer , to purchase or sell , any shares and should not be considered as a recommendation that any investor should subscribe for or purchase any of PIIL's shares . Neither this presentation nor any other documentation or information ( or any part thereof ) delivered or supplied under or in relation to the shares shall be deemed to constitute an offer of or an invitation by or on behalf of PIIL . This presentation should be read in conjunction with the financial statements included herein . PIIL , as such , makes no representation or warranty , express or implied , as to , and does not accept any responsibility or liability with respect to , the fairness , accuracy , completeness or correctness of any information or opinions contained herein . The information contained in this presentation , unless otherwise specified is only current as of the date of this presentation . PIIL assumes no responsibility to publicly amend , modify or revise any forward - looking statements , on the basis of any subsequent development , information or events , or otherwise . Unless otherwise stated in this document , the information contained herein is based on management information and estimates . The information contained herein is subject to change without notice and past performance is not indicative of future results . PIIL may alter , modify or otherwise change in any manner the content of this presentation , without obligation to notify any person of such revision or changes . This presentation may not be copied and disseminated in any manner . PIIL will not be in any way responsible for any action taken based on such forward - looking statements . THE INFORMATION PRESENTED HERE IS NOT AN OFFER OR SOLICITATION OF ANY OFFER TO PURCHASE OR SELL ANY EQUITY SHARES OR ANY OTHER SECURITY OF PI INDUSTRIES LTD . P
Page 2
Agenda 2 01 Consolidated Financial Performance 02 Key Updates 03 Business Model & Strategy 04 ESG Initiatives 05 Awards & Recognition Agenda 01 Consolidated Financial Performance 02 Key Updates 03 Business Model & Strategy 04 ESG Initiatives 05 Awards & Recognition
Page 3
Growth Softened amid Cyclical headwinds and global disruptions... Transitioning towards growth trajectory FINANCIALS Q1FY27 (Consolidated) 17,023 3,693 Commercialized 3 new molecules in Exports Trade Working Capital Reduced by 19 Days to 120 Days in Jun - 26 Cash Flow from Operating Activities in Q1FY27 is INR 6,395 Mn. Net Cash balance increased to INR 37,939 Mn 10% 29% 2,442 39% Launched New peptide - based Biological product in the US Revenue EBITDA INR Mn PAT AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL 3 Domestic Biologicals grew 50%+ Y - o - Y in Q1FY27 Standalone Q1FY27: Revenue 10%, EBITDA 20%, PAT 26% FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS Pi Growth Softened amid Cyclical headwinds and global disruptions ... Transitioning towards growth trajectory FINANCIALS Domestic Biologicals grew 50%+ Y-o-Y in QlFY27 Launched w peptide-bo logical produc the US Trade Working Capital Reduced byl9 Days to 720 Days in Jun-26 rating Activiti Y27 is INR 6,39 et Cash balanc eased to INR 37
Page 4
• ~12% decline (Volume down 8%) in Agchem Exports due to soft demand in global agrochemical industry . • Despite challenges, Domestic volume up by ~12% (revenue grew by ~3%) o Biologicals grew aggressively 50 %+ o Pricing under pressure o Delayed monsoon led to partial postponement of sales • PIHS revenue contracted by 25% Y - o - Y due to order book phasing and customer delivery schedule. • Increase of input material price due to geo - political issues impacted Gross margin. • Overheads maintained at lower single digit increase. • Net Profit is in line with operating performance and higher ETR. Q1 Performance Reflects Revival in Domestic Business … … Biologicals showing expected growth … 13.3 % 2 .8 % 38.9% 29.2% INR Mn Q1FY26 Q1FY27 % YoY Revenue 19,005 17,023 (10)% Gross Margin 57% 57% (69)bps Overheads 5,723 5,984 5% EBITDA 5,219 3,693 (29)% EBITDA Margin % 27% 22% (577) bps Net Profit 4,000 2,442 (39)% 4 Q3FY25 Q3FY26 INR Mn Q1FY26 Exports Revenue Domestic Revenue Q1FY27 EBITDA PAT Q1FY26 Q1FY27 15,620 3,385 5 ,219 4,000 13,542 3,481 3,693 2,442 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL INR Mn Q4FY26 15,652 58% 5,684 3,373 22% 2,002 FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS Ql Performance Reflects Revival in Domestic Business Biologicals showing expected growth T 13.3% 15,620 INR Mn 13,542 ..A.. 2.8% 3,385 3.481 ■ Exports Revenue Domestic Revenue QlFY26 ■ QlFY27 T 29.2% 5,279 3,693 I EBITDA QlFY26 ■ T 3B.9% 4,000 2.442 I PAT QlFY27 -12% decline (Volume down 8%) in Agchem Exports due to soft demand in global agrochemical industry. Despite challenges, Domestic volume up by -12% (revenue grew by -3%) Biologicals grew aggressively 50%+ Pricing under pressure Delayed monsoon led to partial postponement of soles PIHS revenue contracted by 25% Y-o-Y due to order book phasing and customer delivery schedule . Increase of input material price due to geo-politicol issues impacted Gross margin. Overheads maintained at lower single digit increase. Net Profit is in line with operating performance and higher ETR.
Page 5
Balance sheet Jun - 25 Mar - 26 Jun - 26 Shareholders Fund 1,06,003 1,12,305 1,14,683 Non Current Liabilities 4 ,122 4 ,365 4,363 Short term debt 3 41 893 955 Other Current Liabilities 5,442 7,136 7,395 Total 1,15,908 1,24,699 1,27,396 Fixed Asset Inc. Goodwill 4 9,034 56,496 58,209 Non current investments & other assets 5 ,922 2 ,994 5,389 Working Capital 1 8,875 25,628 22,383 Cash, Bank & Investments 38,210 35,094 36,969 Other assets 3,867 4,487 4,446 Total 1,15,908 1,24,699 1,27,396 Key Ratios (%) Annualised Debt/ Equity Ratio 0.01 0.02 0.02 Net Sales to Net Fixed Assets 1.75 1.33 1.30 Net Debt - Free Balance Sheet positions us well to navigate volatility and invest in future growth business 66 71 Inventory DIO Trade Receivables DSO 126 112 53 63 Payables DPO 139 120 NWC Days Q4FY26 Q1FY27 • Surplus cash net of Debt is INR 37,939 Mn enabling the Company to pursue future strategic investments for long - term sustainable growth. • Total capex for Q1FY27 stood at INR 2,685 Mn , reflecting continued investment in manufacturing capabilities and research & development innovation. • Net Working Capital reduced by 19 Days AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL 5 INR Mn FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS Pi Net Debt-Free Balance Sheet positions us well to navigate volatility and invest in future growth business Balance sheet Jun-25 Mar-26 Jun-26 Shareholders Fund 1,06,003 l,12,305 1,14,683 Non Current Liabilities 4,122 4,365 4,363 Short term debt 341 893 955 Other Current Liabilities 5,442 7,736 7,395 Total 1,15,908 1,24,699 1,27,396 Fixed Asset Inc. Goodwill 49,034 56,496 58,209 Non current investments & 5,922 2,994 5,389 other assets Working Capital 18,875 25,628 22,383 Cash, Bank & Investments 38,210 35,094 36,969 Other assets 3,867 4,487 4,446 Total 1,15,908 1,24,699 1,27,396 Key Ratios (%) Annualised Debt/ Equity Ratio Net Soles to Net Fixed Assets 0.07 l.75 0.02 7.33 0.02 7.30 INR Mn Surplus cash net of Debt is INR 37,939 Mn enabling the Company to pursue future strategic investments for long-term sustainable growth. Total capex for QlFY27 stood at INR 2,685 Mn, reflecting continued investment in manufacturing capabilities and research & development innovation. Net Working Capital reduced by 19 Days Inventory D10 66 71 Q4FY26 ■ QlFY27 126 Trade 112 Receivables DSO Payables DPO 63 53 NWC Days 139 120
Page 6
6 1995 2020 2025 1961 2030 Reported Revenue CAGR Leading Agri Distribution player Unique approach of partnership with global innovators ~20% Top 5 Global CSM player • First to commence Agchem CSM • Pioneered Biologicals in India • R&D Investment ~20% Innovation led Agsciences • Chemical and Biological product innovation and solution • Geographical expansion: US, LATAM, Mexico and UK ~20% Agsciences - > Lifesciences • Focus on Biological offerings • Bringing PI ’ s novel innovation to markets globally. • Foray into specialty and electronics chemicals • Pharma CRDMO PI Story: From Distribution Economics to Innovation Led Value Compounding driven by Partnership Model Transformation at each stage Consistent Revenue Growth AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL Right to win Innovation mindset Global partnership Strong Balance sheet Execution excellence
Page 7
Innovation Pipeline Delivering Differentiated, High - Value Crop Solutions … Strengthening Market Position Dorito ® Pressedo ® Osheen Ultra ® Claret ® Unique combination of systemic and contact insecticide Solju Gr & Solju SP Kaprigin ® Eketsu 1 st 3 - way Rice Herbicide Pilin ® Bio - fungicide with Novel Mode Of Action Aminogrow Activ Amino acid & Peptides product Campana New systematic insecticide BYROCK ® Vachan Alcor ® S ystemic herbicide for management of ALS resistance weeds Comet ® Post emergent herbicide for control of grasses Robust pipeline of 20+ products at different stages of development and registration Uranus ® For Mites control Broad spectrum novel insecticide For sucking pest control Unique microbial biofertiliser Broad spectrum insecticide Fungicide Organic Fertiliser Insecticide for Leps management Fixit ® Herbicide for Rice weeds control Kadett ® Combination Fungicide RICE HORTICULTURE CHILLI WHEAT CORN SUGARCANE Crop Solutions COTTON SOYBEAN FY25 FY24 FY26 7 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS Innovation Pipeline Delivering Differentiated, High-Value Crop Solutions Strengthening Market Position HORTICULTURE Alcor Systemic herbicide for management of ALS resistance weeds Pressedo Osheen Ultra I Comet Post emergent herbicide for control of grasses Dorito Uranus For Mites control Fixit Herbicide for Rice weeds control Vachan ™ SOYBEAN CHILLI SUGARCANE Broad spectrum For sucking Solju™ Gr & Solju™ SP Unique microbial biofertiliser Broad spectrum insecticide BYROCK Fungicide Kaprigin Organic Fertiliser Insecticide for Leps RICE novel insecticide pest control Claret Eketsu ™ Unique combination of systemic 1st 3-way Rice and contact insecticide Herbicide Kadett Combination Fungicide Pilin Bio-fungicide with Novel Mode Of Action Aminogrow Activ™ Amino acid & Peptides product management Campana ™ New systematic insecticide Robust pipeline of 20+ products at different stages of development and registration WHEAT CORN CII C 0 +i :::, 0 C/) CL 0 ... 0
Page 8
INR Mn Q1FY26 Q1FY27 % YOY Revenue 723 542 (25)% PBT * (582) (617) (6)% PIHS: Build - up of a differentiated CRDMO platform for long - term growth … * Post intercompany eliminations AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL Expanding & enhancing GMP site in Lodi, Italy; non - GMP in India Building relationships with Biotech & Big Pharma through Global Business Development Strengthening the Regulatory capabilities to be Best - in - Class Leveraging PI ’ s Scientific & Business Process Capabilities for Pharma Slowdown in biotech funding and geopolitical challenges Way Ahead 8 • Q1FY27 revenue decline is mainly due to customer order phasing . • 4 marquee customers onboarded . • Signed up as an exclusive partner for Integrated Drug Discovery with Biotech. • Renewed AIFA GMP Certification for Lodi Site . • Obtained QC Lab GMP Certification at Lodi . • Capex ~INR 233 Mn to expand CDMO capacity, buil d up QC & Kilolab facilities in Lodi and Biology lab in Hyderabad . FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS PIHS: Build-up of a differentiated CRDMO platform for long-term growth INRMn QlFY26 723 (582) QlFY27 542 (677) %YOY (25)% (6)% Revenue * PBT * Post intercompany eliminations Expanding & enhancing GMP site in Lodi, Italy; non-GMP in India Building relationships with Biotech & Big Pharma through Global Business Development Strengthening the Regulatory capabilities to be Best-in-Class Leveraging Pl s Scientific & Business Process Capabilities for Pharma J Slowdown in biotech funding and geopolitical challenges QlFY27 revenue decline is mainly due to customer order phasing. 4 marquee customers on boarded. Signed up as an exclusive partner for Integrated Drug Discovery with Biotech. Renewed AIFA GMP Certification for Lodi Site. Obtained QC Lab GMP Certification at Lodi. Copex -INR 233 Mn to expand CDMO capacity, build up QC & Kilolab facilities in Lodi and Biology lob in Hyderabad. 8
Page 9
Biologicals - From Foundation to Acceleration: Registered, Resourced, and Ready • 2 nd generation product Harpin αβ commercialized in 25+ countries • Nematicide peptide product performing at par with leading chemical nematicides • In dustry ’ s 1 St nematicide for foliar application • Strong field performance of peptide products in farmer's fields covering 5M+hectares in Brazil • Newly registered PHC949 being tested in the US • Ramping up market activities in Brazil, Mexico, Europe & the US: • 5 00+ field trials; 1,000+ growers • Strengthening relationships with key influencers and stakeholders 9 Continued investments in market and product development in focused geographies Building relationships with distributors in focused geographies Investing to upgrade capabilities in R&D for peptides innovation and development Filing label expansion of peptides in the US, Brazil & Mexico Building global product portfolio and brands Biostimulants Soil & Nutrition Solutions Biocontrol FINANCIALS / KEY UPDATES / ESG / AWARDS / BUDINESS MODEL us Biostimulants Soil & Nutrition Solutions Biocontrol ~ Saari ~ Teikko ~ Pl LIN Polj,o~lnOZlneSalt S~ Sc ~ c#PLANT PREzyni ~ Moshy '" Continued investments in market and product development in focused geographies 4 Building relationships with distributors in focused geographies ----- . • . -~ Investing to upgrade capabilities in R&D for peptides innovation and development Building global product portfolio and brands Filing label expansion of peptides in the US, Brazil & Mexico
Page 10
Long - term growth outlook remains intact... Long - term Outlook Remains Intact … Continuing investments in new businesses and product launches for future growth … Margin discipline, scaling platforms. Exports: Technology focused approach to drive incremental business Domestic: Focus on portfolio diversification and product reach through revamped GTM Strategy Health Science: Building a differentiated play in Pharma C R DMO space Progressing on strategic initiatives in line with plan • Commodity prices showing a positive trend • Increase in input costs due to on - going geopolitical tensions leading to pricing pressure • Delayed and uneven monsoon has impacted Kharif sowing • Biological business continues to gain traction • Commercialization of PI ’ s own NCE, subject to regulatory approvals; additional leads progressing well with partnership model • Robust global pipeline of Chemical and Biological products across various development stages • Continuing evaluation of inorganic opportunities in the long - term • 5+ new products to be launched in FY27, expected to accelerate growth • Momentum in new enquiries and conversion to continue • Order book continues to support growth outlook for new products in FY27 • Generics pressure continues with Global Agrochemical companies • Build - up of pipe - line projects through new strategic partnerships entered in last 12 months • Improved business development and R&D pipeline visibility over the next 1 - 2 years • Expanding and enhancing capabilities of GMP site in Lodi, Italy; Non GMP sites in India AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL 10 FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS Long-term Outlook Remains Intact Conti nu in investments in new businesses and product launches for future growth l;lii Domestic: Focus on portfolio diversification and product reach through revamped GTM Strategy Lh '-A~ Exports: Technology focused approach to drive incremental business ~ Health Science: Building a differentiated play in Pharma CRDMO space 00b Progressing on strategic initiatives in line with plan Commodity prices showing a positive trend Increase in input costs due to on-going geopolitical tensions leading to pricing pressure Delayed and uneven monsoon has impacted Kharif sowing Biological business continues to gain traction 5+ new products to be launched in FY27, expected to accelerate growth Momentum in new enquiries and conversion to continue Order book continues to support growth outlook for new products in FY27 Generics pressure continues with Global Agrochemical companies Build-up of pipe-line projects through new strategic partnerships entered in last 72 months Improved business development and R&D pipeline visibility over the next 7-2 years Expanding and enhancing capabilities of GMP site in Lodi, Italy; Non GMP sites in India Commercialization of Pl sown NCE, subject to regulatory approvals; additional leads progressing well with partnership model Robust global pipeline of Chemical and Biological products across various development stages Continuing evaluation of inorganic opportunities in the long-term
Page 11
11
Page 12
• Top 5 worldwide in AgChem CSM • 70% + revenue from proprietary products PI: Trusted, Resilient and Future - Ready • 6 + decades with Global innovators • Zero conflicts till date • Fully integrated R&D across all disciplines under one roof • Rapid tech adoption • ESG, the way of life • Featured in the S&P Global Sustainability Yearbook 2026 • Never a “ me - too” player • New frontiers Agri | Horticulture | Biologicals | Health Sciences A Trusted Brand & Partnerships Science & Technology ESG Anchored Addressing Emerging Opportunities Successful Product Brands & Services An organization that is committed to excellence in whatever it does . . . known for being a Top wealth creator for over 2 decades . . . 12 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL A Trusted Brand Successful Product Science & ESG Addressing Emerging & Partnerships Brands & Services Technology Anchored Opportunities 6+ decades Top 5 worldwide Fulg integrated ESG, the way of life Never a me-too player with Global innovators in AgChem CSM R& across all disciplines under one roof Featured in the S&P New frontiers Zero conflicts 70% + revenue Global Agri I Horticulture I till dote from proprietary products Rapid tech Sustainabilitr Biologicals I Health Sciences adoption Yearbook 2026
Page 13
13 Partnering Across the Ag - chem Value Chain Non conflicting business model … well respected by Global Innovators as Partner • Objective to be high quality producer • Control all processes that impact quality of the end product • Target driven • Ownership at sub - functional level • Ensure consistent, reliable delivery • Continuous de - bottlenecking • Automation • To set benchmarks • Address at source • Safety first culture • A way of life at PI • Build value for Long - term • Protect and build IP Consistent Quality Cost Competitiveness Speed of execution, delivery Reliable & Adaptable Real - time monitoring & review Customer Needs Business Strategy Development Scale - up Manufacturing Evaluation & Trials Regulatory services & Registrations Marketing & Distribution Discovery AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL 13 Cost Competitiveness Speed of execution, delivery Reliable & Adaptable
Page 14
v 1 st Indian company to innovate “ P IOXANILIPROLE ” Now filed for registration World - class R&D set - up delivering innovative and disruptive solutions State - of - the - art R&D Labs at 4 locations NABL ISO17025 and GLP certified New ICP - OES Addition of UPLC - CAD (Charged Aerosol Detector) 90+ projects a t different development stages 70 0+ Scientists incl. 200+ Doctorates R&D 260+ Patents t ill date w ith 10 patents in Q1FY27 In - house library with a vast array of knowledge resources 14 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS World-class R&D set-up delivering innovative and disruptive solutions State-of-the-art R&D Labs at 4 locations 700+ Scientists incl. 200+ Doctorates 260+ Patents till date with 70 patents in QlFY27 NABL IS017025 and GLP certified New ICP-OES Addition of UPLC-CAD (Charged Aerosol Detector) 90+ projects at different development stages In-house library with a vast array of knowledge resources
Page 15
v 15 Consistent Pipeline growing across years … Differentiated CSM Model 90+ molecules are currently in active pipeline with > 6 0% in advanced stages of development 20 molecules have been commercialized over the last few years Ramp - up in Pipeline from Diversified Segments . Non - Agchem ’ s share in new enquiries has increased by 2 5% AgChem continues to Grow; Diversifying Portfolio with new segments like Electronic & Specialty Chemicals.. 15 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL
Page 16
Technology pioneer with technological and IP based interventions in global contract manufacturing Product portfolio consists of early stage molecules with continued thrust to adapt sustainable practices 8 Manufacturing Sites e quipped with Distributed Control System (DCS) spread across 150+ Acres Capital expenditure underway as per plan with 3 MPPs under construction Extensive experience in handling Hazardous Chemistry with over 130 unit processes Flow Technology Vapor Phase Bio Technology Largest Commercial Scale Reactions Agchem CSM, a global leader, backed by strong technological strengths 16 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL FINANCIALS / KEY UPDATES / BUSINESS MODEU / ESG / AWARDS Agchem CSM, a global leader, backed by strong technological strengths Technology pioneer with technological and IP based interventions in global contract manufacturing 8 Manufacturing Sites equipped with Distributed Control System (DCS) spread across 150+ Acres Product portfolio consists of early stage molecules with continued thrust to adapt sustainable practices Extensive experience in handling Hazardous Chemistry with over 130 unit processes Capital expenditure underway as per plan with 3 MPPs under construction
Page 17
17 BENEFITS OF CROSS SELLING OPPORTUNITIES PROCURE REPEAT BUSINESS UNDERLYING PRINCIPLES RESPECT & DEVELOP IP REPUTATION OF TRUST & RELIABILITY FORGE RELATIONSHIP Crop Solutions Channel Enablers Digi - tech @Core Farmers Engagement Efficiency Excellence Domestic Business – Brands Strong Partner Having experience more than 6 decades 25+ Global Innovators Strong Pipeline Molecules based on crop solutions and Indian needs • Extension & product development & stewardship (team experience in handling complex new - age premium chemistries) • Strong relationship with stakeholders • Policy level by participation Farmers & Extensive Distribution Network 25 stock points; 15K+ distributors; 100K+ retail points • Crop solution approach focussing farmer & using ICT (Information, Communication and Technology) • Organization structure empowered with digi tech to support and demonstrate value delivery to farmers • Online analytics tools for farmers and employees • I nnovative Ideas and branding for enhancing product life cycle • Experience of successfully managing transition of products from patented to generic • Application services for development & engagement FOCUS ON INNOVATION Evaluation & Trials Regulatory services & Registrations Marketing & Distribution Differentiated Domestic Distribution Model Driven By Unique Solutions through Global Partnerships, Brands Building Capabilities And Market Reach More than 6 decades creating market - leading brands Significant revenue from leading Brands in the market, some brands are more than a decade old AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL FINANCIALS / KEY UPDATES / BUSINESS MOD EU / ESG / AWARDS Differentiated Domestic Distribution Model Driven By Unique Solutions through Global Partnerships, Brands Building Capabilities And Market Reach Strong Partner Having experience more than 6 decades 25+ Global Innovators ----------- Strong Pipeline Molecules based on ...... crop solutions an~ Indian needs Extension & product development & stewardship (team experience in handling complex new-age premium chemistries) Strong relationship with stakeholders Policy level by participation Evaluation & Trials Domestic Business Brands Regulatory services & Registrations Marketing & Distribution Crop Solutions PROCURE REPEAT BUSINESS FOCUS ON INNOVATION UNDERLYING PRINCIPLES RESPECT & DEVELOP IP BENEFITS OF CROSS SELLING OPPORTUNITIES REPUTATION OF TRUST& / RELIABILITY FORGE RELATIONSHIP 0 Digi-tech @Core Engagement Efficiency Excellence Farmers Channel More than 6 decades creating market-leading brands Farmers & Extensive Distribution Network 25 stock points; 15K + distributors; lOOK + Crop solution approach focussing former & using ICT (Information, Communication and Technology) Organization structure empowered with digi tech to support and demonstrate value delivery to farmers Online analytics tools for farmers and employees Innovative Ideas and branding for enhancing product life cycle Experience of successfully managing transition of products from patented to generic Application services for development & engagement • Enablers Significant revenue from leading Brands in the market, some brands are more than a decade old 17
Page 18
40+ Countries 10+ Overseas Offices 8 Mfg. Sites 25 Stock Points 4,000+ Employees 100,000+ Retail Points 15,000+ Distributors Dusseldorf Beijing India Tokyo Sao Paulo Amsterdam Milan Our Markets Overseas Offices Mexico City Dubai Seattle St. Louis 2,000+ Contract employees Registered Office Corporate Office R&D Manufacturing Units Depots India Strong understanding of international work culture with 60+ years of deep - rooted relationships Our Global Presence 18 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL London Almeria
Page 19
Multipronged strategy to sustain the growth momentum backed by multiple growth engines & M&A Prudent capital allocation to ensure the long - term shareholder value creation Deepening our technological capabilities to open new horizons Multiple Growth Engines / Levers De - risk Proces s Digital • Innovation Chem - Bio • Manufacturing concentration • New formulation of existing products • Information integration • Decision tools • AI • Chemistry • Block Builders • Process engineering • Flow Expansion Creation Segments Operational Excellence Brands Research and process innovation with global partnerships Marketing & Distribution - Product Pipeline Biologicals Platforms PI Health Sciences - CRDMO Market Inorganic Disruptive Value - added Technologies Product Assets Niche verticals within Pharma/ Specialty chemicals High growth application areas having synergy Build Customer Intimacy Product & Services IP De - risk & Create Inorganic Value creation Organic Grow Smart 19 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL FINANCIALS / KEY UPDATES / BUSINESS MODEU / ESG / AWARDS Multipronged strategy to sustain the growth momentum backed by multiple growth engines & M&A al Market X Expansion - . Q,, Creation ~ Segments {§} Operational Excellence 0 Brands £ 0 Disruptive Value-added Technologies Product Assets Niche verticals within Pharma/ Specialty chemicals ,£. High growth application areas having synergy Deepening our technological capabilities to open new horizons 0 De-risk 0 Process g Digital Innovation Chem-Bio Chemistry Information Manufacturing Block Builders integration concentration Process Decision tools New formulation engineering Al of existing products Flow C, Multiple Growth Engines/ Levers 0 Research and process innovation with global partnerships 0 Marketing & Distribution - Product Pipeline 0 Biologicals Platforms 0 Pl Health Sciences - CRDMO @ Prudent capital allocation to ensure the long-term shareholder value creation
Page 20
20 The PI Investment Case: A Proven Growth Engine … Unlocking the Next Era of Growth Demonstrated ability to constantly reinvent itself over 8 Decades Guided by our Values Constantly Differentiating our Business to create Moats with Excellence from Ag distribution to CSM to Innovation in Ag; now to Life Sciences Demonstrated Wealth Creation with Strong Financials Debt free balance sheet, War chest of growth capital Digital Edge From Assets to knowledge, to offer consistency with speed ESG, a Way of Life at PI Top 2% ESG - rated globally, 3 rd consecutive year of S&P CSA yearbook World - class Integrated R&D capabilities from discovery to markets: Science & Technology, our Passion Unique Business Model and Strong Global Relationships with Partners from Innovation to Markets People First Constantly building, acquiring and growing our Human Talent globally 20 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL Demonstrated ability to constantly reinvent itself over 8 Decades Guided by our Values World-class Integrated R&D capabilities from discovery to markets: Science & Technology, our Passion Constantly Differentiating our Business to create Moats with Excellence from Ag distribution to CSM to Innovation in Ag; now to Life Sciences Digital Edge From Assets to knowledge, to offer consistency with speed Demonstrated Wealth Creation with Strong Financials Debt free balance sheet, War chest of growth capital People First Constantly building, acquiring and growing our Human Talent globally Unique Business Model and Strong Global Relationships with Partners from Innovation to Markets ESG, a Way of Life at Pl Top 2% ESG-rated globally, 3rd consecutive year of S&P CSA yearbook
Page 21
Classification | PI Confidential Embedding sustainability into long - term value creation 21 Carbon emissions intensity in terms of revenue from operations (INR million) Water intensity in terms of revenue from operations ( INR million) Chemical Oxygen Demand (in MT) Key Highlights* SDG Alignment Environment – Climate change 70% of enrolled youth placed through skill development initiatives 546,000+ healthcare beneficiaries through Mobile Health units and 1 5 7 ,000+ students impacted through various initiatives since FY21 Increased employees ’ average training hours per FTE by 13 % from FY2 5 Women in STEM positions increased to 15.5% in FY ’ 26 from 13.8% in FY ’ 25 800+ acres brought under sustainable agricultural practices by educating farmers about climate - resilient agricultural practices in Q1FY27 * As on 31-Mar-26 Environment – Climate change Environment – Energy management Lost Time Injury Frequency Rate (LTIFR) Environment – Water management 0 for all employees and workers 0 for contractual workers Water intensity increased by ~16% from FY26 Reduced Chemical Oxygen Demand by ~8% vs Q1FY26 Key Highlights * ~16% renewable energy as a share of total electricity consumption vs. FY21 Reduced CO 2 emission intensity by 7%+ from FY26 Environmental Social and Governance • For the 2025 edition, more than 8,551 companies were assessed, and only 540 companies secured a place in the Yearbook, including 32 from India. PI Industries is proud to be among the Top 2 percentile of ESG - rated companies worldwide. • PI ranks among the Top 25 companies globally in the chemical sector and is one of only three Indian chemical companies to be included in the 2025 Yearbook. Score 2024 68 2025 77 Featured in the S&P Global Sustainability Yearbook for 3 rd consecutive year PI Industries Limited has been included in the Dow Jones Best in Class (DJ BIC) Indices for Emerging Markets 1.99 2.46 2.29 FY25 FY26 Q1FY27 8.23 9.92 11.49 FY25 FY26 Q1FY27 23.46 19.67 5.4 FY25 FY26 Q1FY27 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / AWARDS Embedding sustainability into long-term value creation Environmental Social and Governance ■-. SDG Alignment Environment Climate change Environment Climate change Environment Energy management Environment Water management LostTime Injury Frequency Rate (L TIFR) Key Highlights* Reduced CO, emission intensity by 7%+ from FY26 Reduced Chemical Oxygen Demand by -8% vs QlFY26 -16% renewable energy as a share of total electricity consumption vs. FY2l Water intensity increased by -16% from FY26 0 for all employees and workers 0 for contractual workers II II 11 11 Key Highlights* Increased employees average training hours per FTE by 13% from FY25 Women in STEM positions increased to 15.5% in FY 26 from 73.8% in FY 25 800+ acres brought under sustainable agricultural practices by educating farmers about climate- resilient agricultural practices in QlFY27 70% of enrolled youth placed through skill development initiatives 546,000+ healthcare beneficiaries through Mobile Health units and 157,000+ students impacted through various initiatives since FY2l Featured in the S&P Global Sustainability Yearbook for 3rd consecutive year Pl Industries Limited has been included in the Dow Jones Best in Class (DJ BIC) Indices for Emerging Markets 2024 2025 Score 68 77 Pl ranks among the Top 25 companies globally in the chemical sector and is one of only three Indian chemical companies to be included in the 2025 Yearbook. For the 2025 edition, more than 8,551 companies were assessed, and only 540 companies secured a place in the Yearbook, including 32 from India. Pl Industries is proud to be among the Top 2 percentile of ESG-rated companies worldwide.
Page 22
Our commitment to Community... HEALTH & HYGIENE WOMEN EMPOWERMENT EDUCATION & SKILL DEVELOPMENT ENVIRONMENT SUSTAINABILITY 66 villages, Shvastha Seva 26,200+ beneficiaries in Q1FY27 80 rural villages active 6,500+ women benefited ~25% income increase via programs 135 schools with digital learning 80+ youth trained in Q1FY27 1,500+ farmers reached in Q1FY27 ~800+ acres covered in Q1FY27 5,500+ trees restored & planted in Q1 FY27 Building strong, healthy communities across India through targeted CSR programs 22 AWARDS FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL
Page 23
Recognition Reinforces Leadership, Safety & Governance Excellence India's Top Value Creator 2025 Agro Chemicals by Dun & Bradstreet Most Preferred Workplace 2025 - 26 by Marksmen Daily British Safety Council Sword of Honour – Udaipur Site, October 2025 PI Industries receives the Business Leader of the Year – ESG Award from Chemtech Leadership & Excellence Awards 2026 23 4 th EDITION FINANCIALS / KEY UPDATES / ESG / / BUSINESS MODEL AWARDS FINANCIALS / KEY UPDATES / BUSINESS MODEL / ESG / mm Recognition Reinforces Leadership, Safety & Governance Excellence ''+ BRITISH ..illllll SAFETY ,, COUNCIL .A11111111 Sword ~ _... of Honour ~ _. 2025 Winner
Page 24
24 Thank You